Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Operating Leases (2019 - 2025)

Viking Therapeutics' Operating Leases history spans 4 years, with the latest figure at $630000.0 for Q4 2024.

  • For Q4 2024, Operating Leases fell 32.69% year-over-year to $630000.0; the TTM value through Dec 2024 reached $630000.0, down 32.69%, while the annual FY2024 figure was $630000.0, 32.69% down from the prior year.
  • Operating Leases for Q4 2024 was $630000.0 at Viking Therapeutics, down from $755000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.5 million in Q1 2022 and bottomed at $630000.0 in Q4 2024.
  • The 3-year median for Operating Leases is $851000.0 (2023), against an average of $972833.3.
  • The largest annual shift saw Operating Leases decreased 25.71% in 2023 before it tumbled 32.69% in 2024.
  • A 3-year view of Operating Leases shows it stood at $1.3 million in 2022, then fell by 25.71% to $936000.0 in 2023, then crashed by 32.69% to $630000.0 in 2024.
  • Per Business Quant, the three most recent readings for VKTX's Operating Leases are $630000.0 (Q4 2024), $755000.0 (Q3 2024), and $766000.0 (Q2 2024).